Sera Prognostics

Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sera Prognostics reports revenue growth and innovation drive amidst challenges

Sera Prognostics demonstrated strong financial performance with revenue growth and reduced net loss in Q4 2022.
The company's focus on innovation, new data, and upcoming studies positions it well for future growth and market success.
Challenges in revenue expectations and payer dynamics require strategic navigation, but opportunities from studies and technology advancements are promising.

Sera Prognostics reports robust Q1 performance amidst revenue challenges

Sera Prognostics demonstrated strong performance in Q1 2023 with notable revenue growth and positive trial outcomes, showcasing its research capabilities and commitment to innovation.
While facing challenges in revenue projections and financial losses, the company's strategic focus on cost efficiency and strong cash reserves provide a foundation for future growth.
Opportunities lie in upcoming study analyses, continued research efforts, and potential partnerships, positioning Sera Prognostics for sustainable development and market expansion.

Sera Prognostics reports stable Q2 revenue, eyes growth opportunities

Sera Prognostics demonstrated stable financial performance in Q2 2023, with a focus on revenue growth and cost management.
The company's PreTRM test showed promising results in reducing neonatal length of stay, enhancing its market position.
While facing challenges in commercialization and global scaling, Sera has opportunities to expand revenue streams and strengthen partnerships.

SERA reports Q3 revenue growth, focuses on expense management

SERA's financials show revenue growth potential with a focus on expense management
Balancing product development and study outcomes crucial for future success
Strategic steps taken to ensure operational sustainability and revenue growth

Sera Prognostics reports positive study outcomes amidst financial challenges

Sera Prognostics demonstrated positive study outcomes with potential for improved neonatal health, despite a net loss in Q4 2023.
Strategic focus on managing expenses, leveraging study results, and achieving key milestones for future revenue growth.
Opportunities lie in lower cash expenses for 2024, revenue growth initiatives, and the launch of a blood sample self-collection device.
Challenges include balancing financial performance, cash management, and addressing analyst inquiries.

Sera Prognostics reports improved Q1 financials and eyes global expansion

Sera Prognostics made strides in financial performance and operational efficiency in Q1 2024.
The company's focus on expanding test adoption and improving margins shows promise for growth.
Despite challenges like regulatory impacts, Sera Prognostics is poised for strategic investments and market expansion.

Sera Prognostics reports Q2 revenue decline, focuses on growth strategies

Sera Prognostics navigated challenges with decreased revenue and a net loss in Q2 2024, emphasizing cost management and efficiency.
The company's strengths lie in strategic progress, enhanced market visibility, and new market opportunities with the PreTRM Test approval.
Opportunities exist in leveraging study results for product adoption, expanding market reach through awareness initiatives, and utilizing financial flexibility for growth.

Sera Prognostics focuses on combating premature births, strengthens revenue growth

Sera Prognostics is actively working to combat premature birth risks in the U.S.
Despite financial challenges, the company maintains a solid cash position for growth
Strategic initiatives aim to increase revenue and awareness for sustainable progress

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The heavy selling pressure might have exhausted for Sera Prognostics, Inc. (SERA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Sera Prognostics, Inc. (SERA) Loses -13.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Sera Prognostics, Inc. (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Sera Prognostics, Inc. (SERA) Rating Upgrade to Buy

Sera Prognostics, Inc. (NASDAQ:SERA ) Q4 2022 Earnings Conference Call March 22, 2023 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners, IR Greg Critchfield - President and CEO Jay Moyes - CFO Conference Call Participants Patrick Donnelly - Citigroup Dustin Scaringe - William Blair Tom Stevens - TD Cowen Francois Brisebois - Oppenheimer Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to Review Fourth Quarter and Fiscal Year 2022 results. At this time, all participants are in listen-only mode.

Sera Prognostics, Inc. (SERA) Q4 2022 Earnings Call Transcript

SALT LAKE CITY , March 22, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year 2022 ended December 31, 2022. Recent Highlights: Announced positive top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at ChristianaCare in Wilmington, Delaware.

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS

SALT LAKE CITY , March 9, 2023 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2022 financial results on Wednesday, March 22, 2023, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2022 Financial Results on March 22, 2023

SALT LAKE CITY , Feb. 23, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the upcoming Cowen Health Care Conference March 6-8, 2023 in Boston and the Oppenheimer 33rd Annual Healthcare Conference held to be held virtually March 13-15, 2023. Gregory C.

SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES

The stock price of Sera Prognostics Inc (NASDAQ: SERA) surged by 127.69% this past week. This is why.

SERA Stock: 127.69% Surge This Week Explanation

AMC Preferred Equity Unit

Titan Medical Inc

Debunking common myths about trading penny stocks in 2023 The post 3 Common Myths About Penny Stocks Debunked  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Common Myths About Penny Stocks Debunked

PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay SALT LAKE CITY , Feb. 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at ChristianaCare in Wilmington, Delaware. Both co-primary outcomes—reduction of severe neonatal morbidity or neonatal death; and decreased length of neonatal hospital stay—met their endpoints, and the improvements in outcome with a PreTRM® test-and-treat approach were statistically significant.

Sera Prognostics Announces Positive Top-line Data from AVERT PRETERM TRIAL

– Sera's PreTRM® test-and-treat strategy helps build on Fors Marsh's commitment to investing in its employees to enable a healthy and viable workforce – SALT LAKE CITY and ARLINGTON, Va. , Nov. 29, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, and Fors Marsh, a company dedicated to solving complex challenges through market research, are collaborating to provide Sera's PreTRM® Test to employees at Fors Marsh as part of their maternity benefits, effective January 1, 2023.

FORS MARSH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH SERA PROGNOSTICS

- Clinical and economic benefits of the PreTRM® test and treat strategy illustrated amongst diverse racial and ethnic backgrounds - SALT LAKE CITY , Nov. 15, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication of results from a clinical utility and cost-effectiveness modeling study, ACCORDANT (Analyses aCross Congruent studies ReDucing Adverse pregNancy ouTcomes). The newly published study reports: Case management, which consists of increased outreach, education, and specialist care for women predicted to be at higher risk for delivering prematurely, was expected to decrease neonatal and maternal hospital length of stay by 19% (p=0.029) and 8.5% (p=0.001), respectively, compared with standard care.

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA PREDICTING CLINICAL UTILITY AND COST EFFECTIVENESS OF THE PRETRM® TEST-AND-TREAT STRATEGY ACROSS DIVERSE POPULATIONS

Sera Prognostics, Inc. (NASDAQ:SERA ) Q3 2022 Earnings Conference Call November 9, 2022 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners, IR Greg Critchfield - President and CEO Jay Moyes - CFO Conference Call Participants Patrick Donnelly - Citi Andrew Brackmann - William Blair Tom Stevens - Cowen Operator Good afternoon, and welcome to the Sera Prognostics conference call to review Third Quarter Fiscal Year 2022 results. At this time, all participants are in a listen-only mode.

Sera Prognostics, Inc. (SERA) Q3 2022 Earnings Call Transcript

Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 12.50% and 2.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Tops Revenue Estimates

SALT LAKE CITY , Nov. 9, 2022 /PRNewswire/ --  Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter ended September 30, 2022. Recent Highlights: Focus on integrated healthcare systems beginning to show success with the signing on of Banner Health, an innovative leader in healthcare models, for its University Family Care/ AHCCCS Complete Care members covered under a Medicaid plan and serving more than 300,000 members.

SERA PROGNOSTICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS

SALT LAKE CITY , Oct. 27, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2022 financial results on Wednesday, November 9, 2022, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2022 Financial Results on November 9

The value created by applying Sera's PreTRM® test and treat strategy enables savings to be shared in an innovative value-based paradigm SALT LAKE CITY, COPPELL, Texas and SAN MATEO, Calif. , Oct. 4, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, Sonrava Health, a national family of health and wellness companies, and Cerebrae, an innovator in pricing and measuring the financial value of care, are collaborating to provide Sera's PreTRM® Test to members of Sonrava Health's employer-sponsored health insurance program.

SONRAVA HEALTH TO INCLUDE THE PreTRM® TEST IN ITS EMPLOYEE MATERNITY BENEFITS PACKAGE IN COLLABORATION WITH CEREBRAE AND SERA PROGNOSTICS

First and only broadly clinically validated test to provide accurate and actionable information to help reduce the morbidity, mortality, and costs associated with preterm birth   SALT LAKE CITY and PHOENIX , Sept. 22, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, and Banner Health today announced that Sera's PreTRM® Test will be available to Banner – University Family Care/ AHCCCS Complete Care (B – UFC/ACC) members.

BANNER HEALTH, SERA PROGNOSTICS TEAM UP TO PROVIDE PreTRM® TEST TO COVERED PREGNANT MEMBERS

Sera Prognostics, Inc. (NASDAQ:SERA ) Q2 2022 Earnings Conference Call August 10, 2022 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners Greg Critchfield - Chairman, President & Chief Executive Officer Jay Moyes - Chief Financial Officer Conference Call Participants Dustin Scaringe - William Blair Dan Brennan - Cowen Operator Good afternoon and welcome to the Sera Prognostics' Conference Call to review Second Quarter Fiscal Year 2022 Results. At this time, all participants are in a listen-only mode.

Sera Prognostics, Inc. (SERA) CEO Greg Critchfield on Q2 2022 Results - Earnings Call Transcript

SALT LAKE CITY , Aug. 10, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter ended June 30, 2022. Recent Highlights: Executed on Sera's strategy of pursuing healthcare systems where administrative and clinical leadership are aligned on incorporating PreTRM testing efficiently as an add-on to comprehensive services provided to pregnant women.

SERA PROGNOSTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS

SERA sells PreTRM®, a CLIA-lab based assay to determine the risk of a woman having a pre-term birth – a birth prior to 37 weeks of gestation. After IPO'ing in July 2021 at $16, the Company has since lost over 80% of its value and trades at 50% of its cash and marketable securities.

A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening

Sera Prognostics, Inc. (SERA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sera Prognostics, Inc. (SERA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

SALT LAKE CITY, July 28, 2022 /PRNewswire/ -- Sera Prognostics  Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2022 financial results on Wednesday, August 10, 2022, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2022 Financial Results on August 10

SALT LAKE CITY , June 6, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the 42nd Annual William Blair Growth Stock Conference on Tuesday, June 7, 2022 at 3:20 p.m. CT. Gregory C.

SERA PROGNOSTICS TO PRESENT AT 42nd ANNUAL WILLIAM BLAIR GROWTH STOCK CONFERENCE

Results show that the validated proteomics predictor has even greater predictive performance to determine risk of spontaneous preterm birth SALT LAKE CITY , May 19, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication of improved PreTRM® test performance using women from the Proteomic Assessment of Preterm Risk (PAPR) clinical study whose pregnancy outcomes are aligned with updated ACOG gestational age dating guidelines. The newly published article reports: A greater observed sensitivity of 88% at 75% specificity, which represent increases of 17% and 1%, respectively, relative to all subjects An improved performance was also demonstrated over an expanded 18-20 weeks' gestational age time interval for performing PreTRM testing, consistent with the timeframe of routine obstetric visits during pregnancy A negative predictive value of 99% for the test, at its validated threshold "Beyond increased performance, these data show that the PreTRM® test can also be offered more conveniently to women over a broader time interval during pregnancy, typically months before preterm delivery occurs," said Michael Foley, MD, Sera's Chief Medical Officer.

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING IMPROVED PERFORMANCE OF ITS PRETRM® TEST WITH MORE PRECISE GESTATIONAL AGE

SALT LAKE CITY , May 18, 2022 /PRNewswire/ --  Sera Prognostics  Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today presented data demonstrating the health and economic benefit of the PreTRM® test-and-treat strategy. The presentation titled "Clinical and Economic Utility of a Proteomic Biomarker Preterm Birth Predictor: Analysis of a Large and Diverse Pregnancy Cohort" was given by lead author Julja Burchard today at the ISPOR (The Professional Society for Health Economics and Outcomes Research) 2022 international conference in Washington DC, Session 5 from 9:00-12:45 PM.

News for Sera Prognostics Stock (SERA)